相似文献
1
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.
J Clin Microbiol. 2006 Jul;44(7):2612-4. doi: 10.1128/JCM.00449-06.
2
Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
J Virol. 2005 Sep;79(18):12045-57. doi: 10.1128/JVI.79.18.12045-12057.2005.
3
Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer.
J Clin Microbiol. 2005 Feb;43(2):813-7. doi: 10.1128/JCM.43.2.813-817.2005.
4
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
J Virol. 2014 Aug;88(16):9268-76. doi: 10.1128/JVI.00695-14. Epub 2014 Jun 4.
5
In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
J Virol. 2004 Dec;78(24):13553-61. doi: 10.1128/JVI.78.24.13553-13561.2004.
6
Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies.
J Virol. 2002 Sep;76(18):9253-9. doi: 10.1128/jvi.76.18.9253-9259.2002.
7
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Antimicrob Agents Chemother. 2010 Feb;54(2):907-11. doi: 10.1128/AAC.01080-09. Epub 2009 Dec 7.
8
Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays.
J Clin Microbiol. 2004 Jul;42(7):2907-12. doi: 10.1128/JCM.42.7.2907-2912.2004.
9
Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1.
Antimicrob Agents Chemother. 2005 Aug;49(8):3334-40. doi: 10.1128/AAC.49.8.3334-3340.2005.
10
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Antimicrob Agents Chemother. 2009 May;53(5):2196-8. doi: 10.1128/AAC.01593-08. Epub 2009 Feb 17.
引用本文的文献
1
Complete genome characterization of human noroviruses allows comparison of minor alleles during acute and chronic infections.
Access Microbiol. 2021 Feb 17;3(3):000203. doi: 10.1099/acmi.0.000203. eCollection 2021 Mar.
2
Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study.
Infect Drug Resist. 2020 Oct 22;13:3763-3770. doi: 10.2147/IDR.S272232. eCollection 2020.
3
Fact and Fiction about 1%: Next Generation Sequencing and the Detection of Minor Drug Resistant Variants in HIV-1 Populations with and without Unique Molecular Identifiers.
Viruses. 2020 Aug 4;12(8):850. doi: 10.3390/v12080850.
4
Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping.
Viruses. 2020 Jun 27;12(7):694. doi: 10.3390/v12070694.
5
Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.
J Infect Dis. 2020 Apr 27;221(10):1584-1597. doi: 10.1093/infdis/jiz650.
6
Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
AIDS Res Ther. 2018 Nov 8;15(1):18. doi: 10.1186/s12981-018-0206-y.
7
Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors.
J Clin Microbiol. 2018 Nov 27;56(12). doi: 10.1128/JCM.01443-18. Print 2018 Dec.
8
Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy.
Viruses. 2017 Dec 19;9(12):392. doi: 10.3390/v9120392.
9
Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
Infect Dis Poverty. 2017 Dec 4;6(1):163. doi: 10.1186/s40249-017-0377-0.
10
Efficient and unbiased metagenomic recovery of RNA virus genomes from human plasma samples.
Sci Rep. 2017 Jun 23;7(1):4173. doi: 10.1038/s41598-017-02239-5.
本文引用的文献
1
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
AIDS. 2006 Mar 21;20(5):701-10. doi: 10.1097/01.aids.0000216370.69066.7f.
2
Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates.
J Clin Virol. 2005 Dec;34(4):268-71. doi: 10.1016/j.jcv.2005.01.011.
3
Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.
J Clin Microbiol. 2005 Nov;43(11):5696-704. doi: 10.1128/JCM.43.11.5696-5704.2005.
4
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.
J Clin Microbiol. 2005 Jan;43(1):406-13. doi: 10.1128/JCM.43.1.406-413.2005.
5
Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.
J Infect Dis. 2003 Nov 15;188(10):1433-43. doi: 10.1086/379215. Epub 2003 Nov 3.
6
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Clin Infect Dis. 2003 Jul 1;37(1):113-28. doi: 10.1086/375597. Epub 2003 Jun 23.
7
Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype.
J Infect Dis. 2002 May 15;185(10):1506-10. doi: 10.1086/340215. Epub 2002 Apr 30.
8
Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.
AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):243-8. doi: 10.1089/088922202753472801.
9
Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J.
J Acquir Immune Defic Syndr. 2001 Nov 1;28(3):254-8. doi: 10.1097/00042560-200111010-00008.
10
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.
AIDS. 2001 Nov 9;15(16):2189-91. doi: 10.1097/00002030-200111090-00016.
Zotero 插件